Tecfidera (dimethyl fumarate) is a prescription drug used to treat multiple sclerosis (MS). Tecfidera’s cost may depend on factors such as your dosage, whether you have health insurance, and the ...

Tecfidera’s (dimethyl fumarate) usual dosage for MS and CIS is 120 mg twice per day for 7 days, and then 240 mg twice per day. Tecfidera treats the following conditions: relapsing-remitting multiple ...

TECFIDERA (dimethyl fumarate) 120mg and 240mg delayed-release caps by Biogen Idec Biogen presented new data at ECTRIMS showing that Tecfidera (dimethyl fumarate) significantly reduced multiple ...

Biogen's Tecfidera is on its way to blockbuster status in the highly competitive multiple sclerosis indication. That's great news for Biogen, which needed the drug to succeed in order to protect its ...

A new method replicated the findings of a previous clinical trial of Tecfidera in people with relapsing-remitting MS, a study ...

WESTON, Mass.--(BUSINESS WIRE)-- Data presented today show that TECFIDERA ® (dimethyl fumarate) continues to offer consistent and strong efficacy combined with a favorable safety profile in a broad ...

Biogen’s DTC ad for multiple sclerosis pill Tecfidera has garnered its fair share of criticism from patients who say it’s unrealistic. But that didn’t stop the TV commercial from getting the job done, ...

(Reuters) - A U.S. federal appeals court on Wednesday upheld a ruling that Biogen Inc's patents on its blockbuster multiple sclerosis drug Tecfidera are valid, rejecting a challenge by Danish ...

Warehoused patients, months of Wall Street hype, and positive clinical data all added to the anticipation around Biogen Idec’s Tecfidera MS drug. Months following launch, this Cinderella story—of a ...

On September 2, 2015, the USPTO Patent Trial and Appeal Board (PTAB) denied institution of another Inter Partes Review brought by Kyle Bass, the Coalition for Affordable Drugs, and other related ...

Biogen heads into Q1 earnings with new drugs like Skyclarys and Zurzuvae driving growth as legacy MS products face rising competitive pressure.

Defending its blockbuster multiple sclerosis drug Tecfidera from generics hasn't been easy for Biogen lately, and the painful trend continued this week with a court ruling that clears the way for more ...